Former CFO of Moderna, Amgen, and
3M Brings Decades of Relevant
Experience to the PacBio Board
MENLO
PARK, Calif., Oct. 16,
2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a
leading developer of high-quality, highly accurate sequencing
solutions, today announced the appointment of David Meline to its Board of Directors,
effective October 13, 2023. Mr.
Meline was most recently the Chief Financial Officer of Moderna,
Inc., a global biotechnology and pharmaceutical leader.
"David is a highly respected executive with an extensive track
record for leading companies in several industries through periods
of extraordinary growth," said Christian
Henry, President and Chief Executive Officer of PacBio. "His
experience, from leading Moderna through its transformational stage
to scaling global organizations like Amgen and 3M, makes him an ideal addition to our
board. I look forward to leveraging his deep experience as we
continue scaling PacBio."
Prior to Moderna, Mr. Meline served as the Chief Financial
Officer for Amgen Inc. from 2014 to 2020 and 3M Company from 2008 to 2014, and spent more than
20 years at General Motors Company in various finance and
management roles. Mr. Meline currently serves on the boards of
directors of ABB Ltd., a publicly traded technology company
specializing in electrification, motion and automation solutions,
and the Los Angeles Philharmonic. Mr. Meline will join the board of
directors of HP Inc. effective November
1, 2023. Mr. Meline holds a Bachelor's degree in Mechanical
Engineering from Iowa State University,
a Master's degree in Economics from the London
School of Economics and Political Science, and a Master's
degree in Business Administration from the University of Chicago.
"I am thrilled to join the PacBio Board at this pivotal stage,"
said Mr. Meline. "I've dedicated the latter part of my career to
leading healthcare organizations that leveraged the power of
genomics to develop some of the most groundbreaking therapies, so
naturally, PacBio's mission resonated with me. I believe the
industry has only scratched the surface on how genomics can
transform human health and am eager to help guide the company as it
executes this mission."
About PacBio
PacBio (NASDAQ: PACB) is a premier life science technology
company that is designing, developing and manufacturing advanced
sequencing solutions to help scientists and clinical researchers
resolve genetically complex problems. Our products and technologies
stem from two highly differentiated core technologies focused on
accuracy, quality and completeness which include our HiFi long-read
sequencing and our SBB® short-read sequencing technologies. Our
products address solutions across a broad set of research
applications including human germline sequencing, plant and animal
sciences, infectious disease and microbiology, oncology, and other
emerging applications. For more information, please visit
www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use
Only. Not for use in diagnostic procedures.
Contacts
Investors:
Todd Friedman
ir@pacificbiosciences.com
Media:
Lizelda
Lopez
pr@pacificbiosciences.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/pacbio-announces-appointment-of-david-meline-to-board-of-directors-301957110.html
SOURCE Pacific Biosciences of California, Inc.